TriSalus Life Sciences, Inc. (TLSI)

Over the past six months, TriSalus Life Sciences' stock (TLSI) has experienced a decline of 9.54%, but it has shown an increase of 8.02% compared to the previous week and a 5.57% rise over the last month. Key events impacting the stock include the Q2 2025 Earnings Report, the launch of TriNav FLX, the CFO Appointment, the Q4 and Full Year 2024 Financial Results, a new reimbursement code, a private placement and capital structure simplification, and debt financing.

The provided information does not explicitly detail demand seasonality for TriSalus Life Sciences' products and services. Demand is likely driven by ongoing patient needs, clinical advancements, and healthcare provider adoption rather than typical seasonal consumer patterns. The company has reported consistent revenue growth year-over-year, suggesting a steady demand for its technologies.

TriSalus Life Sciences, Inc. (TLSI) is an oncology company focused on improving outcomes for patients with difficult-to-treat liver and pancreatic cancers, operating within the Healthcare sector, specifically in the Drug Delivery, Medical Specialties, and Biotechnology industries. The company integrates standard-of-care treatments and investigational immunotherapeutics with disruptive pressure-enabled drug delivery infusion systems. Its major products include Pressure Enabled Drug Delivery (PEDD) infusion systems like the TriNav infusion system and TriNav FLX infusion system, as well as Nelitolimod (SD-101), an investigational toll-like receptor 9 (TLR9) agonist.

TriSalus Life Sciences, Inc. is headquartered in Westminster, Colorado, United States. Specific details about its broader international or national geographic footprint beyond its headquarters are not explicitly provided.

TriSalus Life Sciences appears to maintain a positive reputation within its sector, driven by its focus on innovation and growth. Recent news highlights include strong revenue growth and advancements in its TriNav platform. The company's commitment to improving EBITDA performance and achieving cash flow positivity by 2026 also contributes to a positive outlook. The launch of new products like TriNav FLX and the expected positive impact of a new reimbursement code further bolster its standing.

Information on major institutional and individual owners is available through financial platforms. In the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock. However, over the last 12 months, insiders bought 758,109 shares and sold 54,829 shares, resulting in a net activity of 703,280 shares bought. Specific insider transactions include acquisitions by officers and a director, often through non-open market transactions.